Despite of great advances in understanding the diverse mechanisms of stroke damages, thrombolysis with tissue plasminogen activator (tPA) still is the only clinically effective therapy, but fewer than 5% stroke patients receive effective treatment due to the narrow therapeutic window. The gene discussed is PLAT; the disease is Stroke.